News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MDXG under $10
MDXG under $10
MDXG under $10
MDXG under $10
MDXG Chart
Spread 0.07 not so good for shorts to cover 
OK. Here is a recent podcast from Brian Finn of FIN Capital on the MDXG saga. Def worth a listen and then an update from their visit with MiMedx saying finances should be out within a month.
https://anchor.fm/avery-pagan/episodes/Brian-Finn-FIN-Capital-on-Behavioral-Bias-in-the-Stock-Market-ea380b
From FIN Capital Management LLC:
The TAM of AmnioFix injection in the Knee
Market size for pharma drugs for OA for the knee
Their estimates (using Grand View Research's TAM of knee OA):
Currently near $7,000m expanding about 6% YOY.
|
Followers
|
29
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
303
|
|
Created
|
10/27/08
|
Type
|
Free
|
| Moderators | |||
MiMedx® has built a management team with highly experienced healthcare executives with track records of leading large healthcare organizations in generating growth, producing profitability, and increasing shareholder value. Our management team draws on guidance from an insightful board of directors and medical advisory board. Collectively, they are committed to achieving success, accomplishing our corporate goals and growing the company. The management team at MiMedx® includes:
Mr. Wright was appointed Chief Executive Officer effective May 13, 2019. Previously, Mr. Wright served as a Partner at Signal Hill Advisors, LLC, a consulting practice, since February 2011.
Mr. Borkowski, was appointed Interim Chief Financial Officer on June 6, 2018. He previously served as Executive Vice President of MiMedx since April 19, 2018.
Mr. Graves joined MiMedx in July 2018 and brings more than 20 years of pharmaceutical and biotech industry experience to the Company, ranging from compliance and sales management to government affairs.
Mr. Hulse joined MiMedx in December 2019, and brings to MiMedx more than twenty years’ experience in large law firms and life sciences organizations, with significant legal, risk management, compliance and operational expertise.
Dr. Mason was named the Company’s Chief Medical Officer in December 2018. He joined MiMedx in June 2014, in the position of Vice President of Medical Affairs for Clinical Programs. Dr. Mason is a Board Certified Internist, board eligible in Rheumatology and Infectious Diseases, whose experience includes a 27-year pharmaceutical and medical device industry career, with increasing levels of responsibility.
Dr. Koob is the Chief Scientific Officer of MiMedx. He is the senior executive responsible for the overall research direction and oversight of the Company’s product and tissue offerings.
Mr. Harris was named Senior Vice President, Marketing and Business Development in December 2018. He joined MiMedx as Senior Vice President, International in June 2018, bringing to the Company 20+ years of experience in the regenerative medicine, medical device and cell therapy fields. In this role, Mr. Harris is responsible for corporate and product marketing, partnerships and joint ventures, as well as international sales and operations.
Scott Turner, has served as Senior Vice President, Operations and Procurement since April 2017. Mr. Turner oversees supply chain from donor recovery services through distribution as well as procurement, engineering, and facilities.
Dr. Brown joined SpineMedica LLC, an early-stage predecessor company to MiMedx, in 2005. She initially served as the Director of Project Management and Senior Engineer for SpineMedica, and later served as its Director of Research and Development and as Vice President of Operations.
Mr. Burrows joined MiMedx Group in April 2011 as Vice President of Wound Care to lead the marketing of the Company’s wound care offerings and other exciting products and tissues. He assumed the role Of Vice President of Global Marketing in August 2011 to focus on expanding the Company’s presence in the regenerative tissue market.
Mr. Spencer is the co-founder of Surgical Biologics, a leading processor of amnion tissue for use in a variety of surgical implants. Since the founding of Surgical Biologics in 2006, he led the development of the proprietary PURION® Process,
About MiMedx
MiMedx® is an industry leader in advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.5 million allografts to date.
Hilary Dixon
Corporate & Investor Communications
770.651.9066
investorrelations@mimedx.com
Estimated Market Cap : $783.0M as of Dec 11, 2019
Outstanding Shares : 110.8M as of December 11, 2018
$1.5M Settlement Recognizes Company's Cooperation & Remediation Efforts
MARIETTA, Ga., Nov. 26, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has finalized a settlement with the Securities and Exchange Commission (the "SEC"), resolving a previously disclosed investigation into the Company's financial accounting practices.
The Company has agreed to settle with the SEC, without admitting or denying the SEC's allegations, by consenting to the entry of a final judgment, subject to court approval, that permanently restrains and enjoins the Company from violating certain provisions of the federal securities laws. As part of the resolution, the Company also agreed to pay a civil penalty in the amount of $1.5 million. The settlement, if approved by the court, will conclude, as to the Company, the matters alleged by the SEC in its complaint.
Dr. M. Kathleen Behrens served as a member of the board of directors of each of Sarepta Therapeutics, Inc. (SRPT), a multi-billion dollar medical research and drug development company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, since March 2009
Mr. Wright was appointed Chief Executive Officer effective May 13, 2019. Previously, Mr. Wright served as a Partner at Signal Hill Advisors, LLC, a consulting practice, since February 2011.
Mr. Barry has served as a director of Elcelyx Therapeutics, Inc., a private pharmaceutical company, since February 2013 and has served as a Managing Member of GSM Fund, LLC, a fund established for the sole purpose of investing in Elcelyx Therapeutics, since February 2013.
Mr. Bierman served as President and Chief Executive Officer of Owens & Minor, Inc., a Fortune 500 company and a leading distributor of medical and surgical supplies, from September 2014 to June 2015.
Mr. Dewberry is a private investor with significant experience at both the management and board levels in the healthcare industry.
Mr. Evans has over 40 years of experience in the healthcare industry. He is currently President of the International Health Services Group, an organization he founded to support health services development in underserved areas of the world.
Mr. Koob joined the law firm of Simpson Thacher & Bartlett, LLP in 1970 and became a partner in 1977.
Mr. Newton has, since 2014, served as Chief Executive Officer and a member of the board of directors of Apollo Endosurgery, Inc. (APEN), a leader in the field of gastrointestinal therapeutic endoscopy.
Dr. Yeston is the Past President of the New England Surgical Society and currently serves as Active Senior Staff, Department of Surgery at Hartford Hospital.
AI
